Trial Profile
A three-part, randomized, placebo-controlled, pharmacokinetic and safety trial of multiple doses of oral CR 845 in hemodialysis patients
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 18 Jul 2017
Price :
$35
*
At a glance
- Drugs Difelikefalin (Primary) ; Difelikefalin
- Indications Pruritus
- Focus Pharmacokinetics
- 12 Jul 2017 Status changed from recruiting to completed as per Cara Therapeutics media release
- 12 Jul 2017 According to a Cara Therapeutics media release, the data from this trial will help to initiate a clinical trial of an oral CR845 pruritus in the non-dialysis CKD-associated pruritus patients in 2017.
- 12 Jul 2017 Top line results are published in the Cara Therapeutics Media Release